

REMARKS

The Office Action and the cited and applied references have been carefully reviewed. No claim is allowed. Claims 47-54 presently appear in this application and define patentable subject matter warranting their allowance. Reconsideration and allowance are hereby respectfully solicited.

Claims 47-54 have been rejected under 35 U.S.C. §112, first paragraph, as containing "new matter". This rejection is made moot by the amendment to the claims to delete the recitation "Variants of the amino acid sequences of the constant regions".

Claims 47-54 have been rejected under 35 U.S.C. §112, second paragraph, as being indefinite. This rejection is also made moot by the amendment to the claims to delete the recitation "Variants of the amino acid sequences of the constant regions".

Claims 47-54 have been rejected under 35 U.S.C. §103(a) as being unpatentable over Taniguchi et al., *J. Immunol. Methods* 206:107-113 (1997), in view of Kohno et al., *Clin. Immunol. Immunopath.* 86(1):11-15 (1998), and Reichman et al., *Nature* 332:323-327 (1998). This rejection is respectfully traversed.

In response to applicant's arguments, the examiner states that "certainty" of success is not a standard to apply in obviousness rejections; rather "reasonable expectation" of success is the standard with which obviousness is determined. However, applicants believe that the combination of Taniguchi and

Kohnno does not give a "reasonable expectation" of success. Kohnno states at page 14, right column, first paragraph:

In humans, elevated levels of biologically active IL-18 were observed in the synovial fluid and serum of patients with rheumatoid arthritis (RA) but not in those with osteoarthritis (Kawashima, M., unpublished results). Furthermore, immunohistochemical staining showed that IL-18-expressing cells were frequently located in both the lining and sublining of the RA synovial tissues. These results suggest that IL-18 may be involved in chronic inflammation and joint detracton in RA patients. Interestingly, markedly elevated levels of biologically active IL-18 were also found in the serum of patients with adult onset Still's disease (Kawashima, M., manuscript in preparation). Although further study is necessary to establish the pathological roles of IL-18 in these diseases, antibodies to IL-18 or antagonists to its receptor might be useful therapeutically. (emphasis added)

As shown above, Kohnno, based on the fact that "elevated levels of biologically active IL-18 were observed in the synovial fluid and serum of patients with rheumatoid arthritis (RA)", states only that "these results suggest that IL-18 may be involved in chronic inflammation and joint detracton in RA patients."

The fact that elevated levels of biologically active IL-18 were observed in the patients suffering from RA can be construed differently. For example, (i) expression of IL-18 may cause RA; (ii) expression of IL-18 may make RA worse; (iii) expression of IL-18 may cure RA; or (iv) expression of IL-18 may be a phenomenon just relating to RA (for example, flowing out of

Appln. No. 09/924,099  
Amd. dated May 20, 2005  
Reply to Office Action of November 30, 2004

IL-18 into blood due to the death of IL-18 producing cells). It is therefore unreasonable to conclude that Kohno suggests that the expression of IL-18 may cause RA.

In fact, Kohno further states that "further study is necessary to establish the pathological roles of IL-18 in these diseases". It is thus clear that Kohno provides no "reasonable expectation of success". No skilled person may be motivated by the teaching of Kohno to use anti-IL-18 antibodies for the treatment of RA.

Attached hereto is a copy of Gracie et al., "A proinflammatory role for IL-18 in rheumatoid arthritis", *The Journal of Clinical Investigation*, Vol. 104, No. 10, 1999. This article shows the experimental results that IL-18 promoted articular inflammation of mice (see page 1398, right column, lines 11-27). The experimental data such as shown in the article may have motivated a skilled person to use anti-IL-18 antibodies for the treatment of RA. However, such experimental data had not been reported and made available at the time the present invention was made.

Contrary to the humanized anti-IL-18 antibodies, Taniguchi discloses only mouse anti-IL-18 antibodies. It appears to applicants that Taniguchi is focused on a method for determining the quantity of human IL-18 with ELISA and pays no attention at all to the administration of IL-18 to humans.

Appln. No. 09/924,099

Amd. dated May 20, 2005

Reply to Office Action of November 30, 2004

Accordingly, one of ordinary skill in the art reading Taniguchi together with Kohno would have no suggestion or motivation to administer an anti-IL-18 antibody to treat RA. As the cited Reichmann reference is only applied for its teaching of how to make a humanized antibody minimizing the anti-globulin response during therapy, it does not satisfy the deficiency of Taniguchi and Kohno in providing a suggestion or motivation to administer an anti-IL-18 to treat RA.

In the present obviousness rejection, the examiner has merely stated that monoclonal antibodies are known, humanized antibodies can be made, and IL-18 plays a role in diseases that include RA. The examiner then concludes from the individual disclosures of the cited and applied references that it would be logical and obvious to a skilled artisan to antagonize the action of IL-18 in treating RA by using an artificially produced peptide capable of neutralizing IL-18, such as a humanized antibody. However, as discussed above regarding suggestion or motivation, the examiner has failed to point to any evidence in the cited and applied references that would motivate or suggest to one of skill in the art that an antibody to IL-18 can be used to treat RA and arrive at the present invention by further humanizing the anti-IL-18 antibody. The Board of Patent Appeals and Interferences. stated in *Ex parte Levengood* 28 USPQ2d 1301, 1302:

In order to establish a *prima facie* case of obviousness, it is necessary for the examiner to present evidence, preferably in the form of some teaching, suggestion, incentive or inference in the applied prior art, or in the form of generally available knowledge, that one having ordinary skill in the art *would have been led* to combine the relevant teachings of the applied references in the proposed manner to arrive at the claimed invention. See, for example, *Carella v. Starlight Archery*, 804 F.2d 135, 231 USPQ 644 (Fed. Cir. 1986); *Ashland Oil, Inc. v. Delta Resins & Refractories, Inc.*, 776 F.2d 281, 227 USPQ 657 (Fed. Cir. 1985).

\*\*\*\*\*

In this case, however, the only suggestion for the examiner's combination of the isolated teachings of the applied references improperly stems from appellant's disclosure and not from the applied prior art. *In re Ehrreich*, 590 F.2d 902, 200 USPQ 504 (CCPA 1979). At best, the examiner's comments regarding obviousness amount to an assertion that one of ordinary skill in the relevant art would have been able to arrive at appellant's invention because he had the necessary skills to carry out the requisite process steps. This is an inappropriate standard for obviousness.

\*\*\*\*\*

That one can *reconstruct* and/or explain the theoretical mechanism of an invention by means of logic and sound scientific reasoning does not afford the basis for an obviousness conclusion unless that logic and reasoning also supplies sufficient impetus to have led one of ordinary skill in the art to combine the teachings of the references to make the claimed invention.

\*\*\*\*\*

Accordingly, an examiner cannot establish obviousness by locating references which describe various aspects of a patent

Appln. No. 09/924,099  
Amd. dated May 20, 2005  
Reply to Office Action of November 30, 2004

applicant's invention without also providing evidence of the motivating force which would impel one skilled in the art to do what the patent applicant has done.

As there is no evidence of motivation to combine the references to arrive at the present invention, there is no *prima facie* case of obviousness.

Reconsideration and withdrawal of the rejection are therefore respectfully requested.

In view of the above, the claims comply with 35 U.S.C. §112 and define patentable subject matter warranting their allowance. Favorable consideration and early allowance are earnestly urged.

Respectfully submitted,

BROWDY AND NEIMARK, P.L.L.C.  
Attorneys for Applicant(s)

By

  
Allen C. Yun

Registration No. 37,971

ACY:pp  
Telephone No.: (202) 628-5197  
Facsimile No.: (202) 737-3528  
G:\BN\S\SUMA\nishida3a\pto\amd final OA 11-30-04.doc

# A proinflammatory role for IL-18 in rheumatoid arthritis

J. Alastair Gracie,<sup>1</sup> Rosalyn J. Forsey,<sup>1</sup> Woon Ling Chan,<sup>2</sup> Ashley Gilmour,<sup>1</sup> Bernard P. Leung,<sup>3</sup> Morag R. Greer,<sup>1</sup> Kirsty Kennedy,<sup>1</sup> Robert Carter,<sup>2</sup> Xiao-Qing Wei,<sup>3</sup> Damo Xu,<sup>3</sup> Max Field,<sup>1</sup> Alan Foulis,<sup>4</sup> Foo Y. Liew,<sup>3</sup> and Iain B. McInnes<sup>1</sup>

<sup>1</sup>Centre for Rheumatic Diseases, University of Glasgow, Glasgow G31 2ER, United Kingdom

<sup>2</sup>Department of Virology, St. Bartholomew and Royal London School of Medicine, University of London, London EC1A 7BE, United Kingdom

<sup>3</sup>Department of Immunology, and

<sup>4</sup>Department of Pathology, University of Glasgow, Glasgow G11 6NT, United Kingdom

Address correspondence to: Iain B. McInnes, Centre for Rheumatic Diseases, University of Glasgow Department of Medicine, 10 Alexandra Parade, Glasgow G31 2ER, United Kingdom.

Phone: 44-141-211-4687; Fax: 44-141-211-4878; E-mail: i.b.mcinnnes@clinmed.gla.ac.uk.

Received for publication May 12, 1999, and accepted in revised form September 22, 1999.

IL-18 is a novel cytokine with pleiotropic activities critical to the development of T-helper 1 (Th1) responses. We detected IL-18 mRNA and protein within rheumatoid arthritis (RA) synovial tissues in significantly higher levels than in osteoarthritis controls. Similarly, IL-18 receptor expression was detected on synovial lymphocytes and macrophages. Together with IL-12 or IL-15, IL-18 induced significant IFN- $\gamma$  production by synovial tissues in vitro. IL-18 independently promoted GM-CSF and nitric oxide production, and it induced significant TNF- $\alpha$  synthesis by CD14<sup>+</sup> macrophages in synovial cultures; the latter effect was potentiated by IL-12 or IL-15. TNF- $\alpha$  and IFN- $\gamma$  synthesis was suppressed by IL-10 and TGF- $\beta$ . IL-18 production in primary synovial cultures and purified synovial fibroblasts was, in turn, upregulated by TNF- $\alpha$  and IL-1 $\beta$ , suggesting that monokine expression can feed back to promote Th1 cell development in synovial membrane. Finally, IL-18 administration to collagen/incomplete Freund's adjuvant-immunized DBA/1 mice facilitated the development of an erosive, inflammatory arthritis, suggesting that IL-18 can be proinflammatory in vivo. Together, these data indicate that synergistic combinations of IL-18, IL-12, and IL-15 may be of importance in sustaining both Th1 responses and monokine production in RA.

*J. Clin. Invest.* 104:1393-1401 (1999).

## Introduction

A critical recent advance in cellular immunology has been the discovery of functionally distinct T-cell subsets, Th1 and Th2, separated on the basis of their cytokine expression. That such functional dichotomy has direct relevance to autoimmune disease has been recognized with the demonstration of distinct roles for Th1 and Th2 responses in several autoimmune models, including collagen-induced arthritis (CIA) and nonobese diabetic (NOD) mice (1-3). Reversal of such T-cell polarization likely confers therapeutic advantage, as immunopathology can be ameliorated or abrogated by administration of cytokines of reciprocal activity (2, 4).

Several data suggest that rheumatoid arthritis (RA) is a "Th1-associated" disease (5-8). However, the factors that initiate and sustain Th1 responses in RA synovium are unclear. Animal and human in vitro studies have demonstrated a critical role for macrophage-derived IL-12 in Th1 cell development (9). Although IL-12 may be detected in RA synovium, the absolute levels present remain unclear (9-11). Recently, a novel cytokine, IL-18, has been cloned that exhibits powerful Th1-promoting activities in synergy with IL-12 (12). Pro-IL-18 is cleaved by IL-1 $\beta$ -converting enzyme (ICE, caspase 1) to yield an active 18-kDa glycoprotein with significant structural

similarity to IL-1 (13). IL-18 induces proliferation, upregulates IL-2R $\alpha$  expression, and promotes IFN- $\gamma$ , TNF- $\alpha$ , and GM-CSF production by Th1 clones (14, 15). IL-18 enhances T-cell and natural killer-cell (NK-cell) cytotoxicity and directly induces IFN- $\gamma$  production by NK cells (16). Synthesis of IL-18 has been described in macrophages, Kupffer cells, keratinocytes, articular chondrocytes, and osteoblasts (15, 17, 18). IL-18 mRNA is upregulated in NOD mice and the murine IL-18 gene maps to the *Idd2* susceptibility locus, suggesting a potential role in predisposition to autoimmunity (19). Moreover protective Th1 responses during murine *Cryptococcus neoformans* or *Yersinia* infections may be abrogated or enhanced by manipulation of IL-18 expression (20, 21).

We therefore sought to identify IL-18 expression in tissues from patients with RA, to establish its potential functional effects within synovial membrane, and to determine those factors that regulate its expression therein. We report here that IL-18 is present in significantly elevated levels in the synovium of patients with RA but not in that of those with osteoarthritis (OA). Together with IL-12 and IL-15, IL-18 induced and sustained articular Th1 cell responses, manifest as IFN- $\gamma$  production. Furthermore, IL-18 independently promoted monokine production, through a direct effect on synovial macrophages.



## Methods

**Reagents.** DMEM, RPMI 1640, glutamine, penicillin/streptomycin, FCS, LPS, and trypsin/EDTA were obtained from Sigma (Poole, United Kingdom), and collagenase was obtained from Worthington Scientific (Lakewood, New Jersey, USA). Recombinant human TNF- $\alpha$  and IFN- $\gamma$  were gifts from G.R. Adolf (Bender Wien, Vienna, Austria). Recombinant human IL-1 $\beta$ , IL-10, IL-12, TGF- $\beta$ , and murine IL-18 were from R&D Systems (Abingdon, United Kingdom).


**Cloning, expression, purification, and biologic activity of human IL-18.** Total RNA was extracted from THP-1 cells (stimulated for 18 hours with human IFN- $\gamma$  [100 U/mL] and LPS [1  $\mu$ g/mL]) using the TRIzol Reagent (Life Technologies, Paisley, United Kingdom). RNA was transcribed into cDNA using SuperScript II RT (Life Technologies) according to a standard protocol. Primer set pairs designed from human IL-18 sequence data were used to clone hIL-18 from the cDNA: sense 5'ATCAGGATCCTTTGGCAAGCTTGAATCTAAATTATC3' antisense 5'ATAGGTCGACTTCGTTTGAACAGTGAA-CATTATAG3' (product 487 bp). The PCR product was confirmed by sequencing, cloned into the pQE-30 expression vector (QIAGEN, Dorking, United Kingdom), and expressed in *Escherichia coli* M15 (QIAGEN). After induction with isopropyl-D-thiogalactoside (BioLine, London, United Kingdom), IL-18 was extracted under native conditions and purified as a 6 $\times$  histidine-tagged fusion protein using a nickel agarose

purification system (QIAGEN) according to the manufacturer's recommendations. Purity was analyzed by SDS-PAGE and Coomassie blue staining, which showed a single-protein band at approximately 23,000. Biologic activity was determined by IFN- $\gamma$  induction from PBMC cultures (12). Cytokines used for in vitro assays were free of LPS as assessed by the limulus amoebocyte assay (Sigma).

**Generation of anti-IL-18 antibodies.** Monoclonal anti-human IL-18 antibodies were generated as described previously (22). Briefly, after immunization and boosting of BALB/c mice with recombinant IL-18, spleen cells were removed for fusion with NS0 cells. Positive clones were selected and checked for specificity by ELISA. Clone D3B6 (IgG1) was chosen for routine use. A polyclonal sheep anti-human IL-18 was raised by standard methods (SAPU, Carlisle, United Kingdom). Confirmatory monoclonal anti-human IL-18 mAb's (clones 1.51E3E1, 3.51D3D4, and 6.42D4D1) were a gift from A. Jackson (Imperial Cancer Research Fund, Leeds, United Kingdom). Antibody specificity was confirmed by Western blotting. Affinity-purified material electrophoresed in 15% SDS-PAGE was transferred onto nitrocellulose (Sigma). After blocking overnight, the membrane was incubated with D3B6, followed by sheep anti-mouse IgG-HRP (Amersham Life Sciences, Little Chalfont, United Kingdom), and developed by enhanced chemiluminescence (Amersham International, United Kingdom). D3B6 bound IL-18 at molecular weight 23,000, but not IL-1 $\beta$  (data not shown).

**Clinical materials and cell preparation.** Synovial membranes (arthroplasty specimens), fluids, and blood samples were obtained from patients with RA and patients with OA satisfying American College of Rheumatology criteria (23). Single-cell suspensions were prepared from membranes as described previously (24). Briefly, tissue fragments were digested with collagenase (2.5 mg/mL) at 37°C for 2 hour, filtered through gauze, and washed. If required, synovial fibroblasts (SFBs) were grown out of primary cell suspensions in 25-cm<sup>2</sup> flasks and used from third to fifth passages (>99% AS02<sup>+</sup> by flow cytometry; Binding Site, Birmingham, United Kingdom). Blood and synovial fluid (SF) mononuclear cell fractions were obtained by density gradient centrifugation through Lymphoprep (Nycomed, Oslo, Norway). Culture was performed at 37°C/5%CO<sub>2</sub> using Nunclon tissue culture plastics (Life Technologies) in RPMI-1640 supplemented with 10% FCS, 2 mM glutamine, 100 IU/mL penicillin, 100 mg/mL streptomycin, and 1.25  $\mu$ g/mL amphotericin B. Cells at  $1 \times 10^6$ /mL were cultured for 48 hours unless otherwise stated. Supernatants were stored at -70°C. SF mononuclear cells for intracellular TNF- $\alpha$  expression were cultured for 4 hours with 10  $\mu$ g/mL Brefeldin A (Sigma).

**Cytokine and cytokine receptor estimation.** IL-18 was measured by ELISA, using either antibodies from R&D Systems or using the mAb D3B6 in conjunction with sheep anti-human IL-18 raised in our laboratories. Briefly, Immulon4 microtiter plates (Dynex, Billingshurst, United Kingdom) were coated with murine monoclonal anti-human IL-18 antibody (R&D Systems or D3B6). Recombinant IL-18 or samples were incubated and detected with either biotin-conjugated goat anti-human IL-18



**Figure 1**  
(a) IL-18 mRNA was detected in RA and OA synovial membranes by RT-PCR (representative of 20 RA and 10 OA tissues). (b) Significantly higher levels of IL-18 were detected in RA SF than in sera (18 matched samples assayed after removal of rheumatoid factor).




(R&D Systems) or biotin-conjugated sheep anti-human IL-18 and developed with Streptavidin-HRP (SAPU) and TMB substrate (Dyner). Rheumatoid factor (RF) was removed from SF by prior incubation with RapiTex beads (Behring Diagnostics, Marburg, Germany). As an additional specificity control and to minimize RF contamination, monoclonal murine anti-IL-1 $\beta$  (R&D Systems) was used as an irrelevant capture antibody, followed by sample, secondary antibodies, and detection system as before. IFN- $\gamma$  was measured by ELISA as already described here, using paired anti-human IFN- $\gamma$  antibodies (gift of T. Meager, National Institute for Biological Standards and Control, Potters Bar, United Kingdom), detection with horseradish peroxidase-conjugated donkey anti-rabbit IgG (Jackson ImmunoResearch Laboratories Inc., West Grove, Pennsylvania, USA), and TMB substrate. GM-CSF was measured by ELISA (Genzyme, Cambridge, Massachusetts, USA). Intracellular TNF- $\alpha$  expression was identified in permeabilized synovial mononuclear populations by FACS analysis (Becton Dickinson, Cowley, United Kingdom) using PE-conjugated monoclonal anti-TNF- $\alpha$  antibody (R&D Systems), together with FITC anti-CD3 or FITC anti-CD14 antibodies (Becton Dickinson). IL-18 receptor expression was determined by FACS analysis using monoclonal anti-human IL-18 receptor antibody (R&D Systems).

**Expression of IL-18 and IL-18R mRNA in synovial tissue.** cDNA was prepared from synovial tissue and fibroblasts using TRIzol extraction (Life Technologies) and RT. IL-18 mRNA was detected using primers described previously for cloning IL-18. Primers for IL-18R were: sense 5'-CCCAACGATAAAGAAGAACGC 3' antisense 5'-TGTCTGTGCCTCCCGTGCTGGC 3' (product 419 bp), and for  $\beta$ -actin: sense 5'-GTGGGGCGCC-CCAGGCACCA 3' antisense 5'-CTC-CTTAATGTCAC GCACG ATTTC 3' (product 548 bp).

**Nitric oxide estimation.** Nitric oxide (NO) was measured as its oxidized product, nitrite, using the Griess reaction (24).

**Immunohistochemistry.** Formaldehyde-fixed paraffin sections (3  $\mu$ m) were stained by a standard Streptavidin-HRP protocol. Product was viewed with 3,3'-dia-minobenzidine tetrachloride (DAB; Sigma) and counterstained with hematoxylin (Sigma). IL-18 expression was quantified by 2 independent observers by light microscopy. Staining was

quantified from 0 to 4 as follows. Lining layer (LL)/interstitial (IS) areas: 0, no staining; 1, <5% positive cells/nuclei per high power field (HPF;  $\times 400$ ); 2, 5-30%; 3, 30-90%; 4, >90%. Lymphocytic aggregate (LA) area: 0, no staining; 1, <5%; 2, 5-20%; 3, 20-40%; 4, >40%. Positive vessels were expressed as percent of total vessels per HPF. For double staining, sections were first stained with anti-IL-18 and developed with SG peroxidase substrate (blue; Vector Laboratories Ltd., Peterborough, United Kingdom). After hydrogen peroxide (Sigma) treatment to quench residual HRP activity, sections were further stained with anti-CD68 or anti-CD3 antibody (DAKO, Ely, United Kingdom) and developed with DAB



**Figure 2**

(a) IL-18 was detected immunochemically (brown) in synovial membrane using anti-IL-18 antibody (D3B6). (b) CD3 localization (brown) in parallel sections indicated IL-18 expression in T cell-rich aggregates. Double staining with anti-IL-18 (blue/black) and (c) anti-CD3 (brown) or (d) anti-CD68 (brown) antibodies, without nuclear counterstain, localized IL-18 mainly to CD68<sup>+</sup> macrophages. Black arrow, double positive; white arrow, IL-18 single positive.

**Table 1**  
Immunolocalization of IL-18 in synovial membrane<sup>a</sup>

	Lining layer	Aggregate	Interstitial	Endothelium
	Mean $\pm$ SD histology score			Percent positive vessels/HPF
RA (n = 18)	0.5 $\pm$ 0.3 <sup>b</sup>	1.7 $\pm$ 0.8 <sup>c</sup>	0.6 $\pm$ 0.5 <sup>c</sup>	5
OA (n = 7)	0.1 $\pm$ 0.1	0	0.03 $\pm$ 0.07	0.4

<sup>a</sup>IL-18 was detected using monoclonal anti-human IL-18 antibody (D3B6). Scores (range, 0-4) were allocated as described in Methods (HPF,  $\times 400$ ). <sup>b</sup> $P < 0.004$ , <sup>c</sup> $P < 0.001$  (Mann-Whitney), RA vs. OA tissues.

(brown), without nuclear counterstain. Negative controls, including the omission of 1 or both primary antibodies or the addition of isotype-matched control antibodies of irrelevant specificity, confirmed the absence of cross-reactivity between anti-IL-18, anti-CD3, or anti-CD68 antibodies. SFBs were formaldehyde fixed in situ in Lab-Tek chamber slides (Nunc) and stained as already described here.

**Induction and assessment of CIA.** CIA was induced as described previously (25). Briefly, male DBA/1 mice (Harlan Olac, Bicester, United Kingdom) were immunized (intradermally) with 200  $\mu$ g of type II bovine collagen (CII; Sigma) in CFA or incomplete adjuvant (IFA; Difco Laboratories, Detroit, Michigan, USA). After intraperitoneal CII (200  $\mu$ g in PBS) challenge on day 21, arthritis development was scored by erythema, swelling, or loss of function per paw (scale 0-3; maximum, 12 per mouse) by a treatment-blind observer. Mice were sacrificed, hind limbs were fixed in 10% neutral-buffered formalin, and 5- $\mu$ m sections were stained with hematoxylin and eosin (Sigma). Mice immunized with CII/IFA also received intraperitoneal injections of either murine IL-18 (100 ng) in PBS/0.1% BSA or PBS/0.1% BSA from day -1 to day 4 and from day 20 to day 24.

**Statistical analysis.** This was performed on Minitab software, (State College, Pennsylvania, USA) using paired *t*

test and Mann-Whitney analyses as appropriate.


## Results

**IL-18 and IL-18 receptor expression in RA synovial membrane.** We sought to identify IL-18 mRNA and protein expression within RA synovial tissues. Using RT-PCR, we demonstrated constitutive IL-18 mRNA expression in 20 of 20 RA synovial samples (Figure 1a) and in 8 of 10 OA samples


examined. IL-18 was detected by ELISA in 12 of 18 SFs obtained from patients with RA (Figure 1b), whereas matched sera typically contained low levels of IL-18 only (SF vs. serum:  $P < 0.005$ ). Prior removal of rheumatoid factor did not alter the levels of IL-18 detected. Moreover, no significant signal was obtained when 8 SFs were assayed using anti-IL-1 $\beta$  antibody as a capture antibody in an otherwise identical ELISA protocol. Thus, neither cross-reactivity with IL-1 nor RF contamination is likely to explain our observations. The median concentration detected in positive samples was 342 pg/mL (interquartile range, 210-1,606), comparable to TNF- $\alpha$  concentrations normally detected in SF (11). IL-12 (p40) concentrations in the SF (median, 82 pg/mL; IQ range, 0-313) did not correlate with those of IL-18. These data clearly indicate that IL-18 is expressed in RA synovial membrane, and, because secretion of IL-18 requires precursor cleavage (13), they strongly suggest that mature IL-18 is present in the synovial compartment.

To determine the distribution of IL-18 expression, we generated an mAb to human IL-18 (clone D3B6) that exhibited a cytoplasmic staining pattern in RA synovial tissues (Figure 2a). Staining was neutralized by prior incubation with recombinant IL-18, but not with the structurally related cytokine IL-1 $\beta$  (data not shown). IL-18 staining was detected in 16 of 18 RA synovia examined. IL-18 expression was most prominent within and adjacent to lymphocytic aggregates (Table 1) and was demonstrated using double staining to reside primarily in CD68<sup>+</sup> macrophages. A small population of CD68<sup>+</sup>, IL-18<sup>+</sup> cells were also detected, likely representing fibroblasts (Figure 2d). These appearances were similar to those in germinal centers in inflamed human tonsil (data not shown). IL-18 staining was also detected within and adjacent to the lining layer, albeit at lower levels (Table 1; Figure 2a). Double staining indicated that this IL-18 expression was predominantly, but not exclusively, found within CD68<sup>+</sup> macrophages. CD3<sup>+</sup> lymphocytes were consistently negative (Figure 2, c and d). This distribution is in contrast to that of other monokines such as IL-1 $\beta$ , TNF- $\alpha$ , or IL-12, which are usually prominent in lining and sublining layer macrophages (10, 11). Expression of IL-18 in endothelial cells was present in 9 of 18 tissues examined at low levels only (5  $\pm$  7% vessels per HPF). Little IL-18 protein was detected in OA synovial membranes (Table 1). Confirmatory immunohistology was performed using a further series of 3 anti-human IL-18 mAbs, raised from discrete clones, which revealed an identical, neutralizable staining pattern in parallel RA synovial tissues (data not shown).

We next sought evidence for IL-18R expression using



**Figure 3**  
(a) IL-18 receptor mRNA expression was detected by RT-PCR in 10 of 10 RA synovial membranes (5 representative data are shown in lanes 1-5). LPS-stimulated THP-1 cells served as positive control. (b) Pooled data (mean  $\pm$  SEM) to characterize IL-18R<sup>+</sup> cells in RA synovial fluid mononuclear cells (n = 8 patients).




**Figure 4**  
Recombinant IL-18 (100 ng/mL), IL-12 (5 ng/mL), and/or IL-15 (100 ng/mL) were added to SF (a) and synovial membrane (b) cultures for 48 hours in the presence (empty boxes) or absence of IL-10 (20 ng/mL)/TGF- $\beta$  (5 ng/mL) (filled boxes), and IFN- $\gamma$  production was determined by ELISA. Data (mean  $\pm$  SEM) are pooled from 10 individual RA patient samples.

reagents specific for its unique  $\alpha$  chain. IL-18 $\alpha$  mRNA was detected by RT-PCR in 10 of 10 RA synovial membranes examined (Figure 3), with product specificity confirmed by sequencing. Cellular expression of IL-18 $\alpha$  protein was characterized by FACS analysis of nonpermeabilized SF mononuclear cells. Significant subpopulations of CD3 $^{+}$  SF lymphocytes and CD14 $^{+}$  macrophages expressed IL-18R (Figure 3).


**IL-18 induced IFN- $\gamma$  production in RA synovial membrane.** The described biologic effects of IL-18 (26, 27) suggested that it might promote synovial inflammation. We therefore investigated the effects of IL-18 on cytokine synthesis by RA synovial tissues in vitro. IL-18 and IL-12 alone induced low levels of IFN- $\gamma$  synthesis by cultures of either SF mononuclear cells or synovial membrane-derived single-cell suspensions (Figure 4). Such synthesis was consistently augmented by addition of IL-18 in combination with IL-12 (Figure 4;  $P = 0.005$  for SF mononuclear cells;  $P = 0.0002$  for synovial membrane-derived single-cell suspensions). Other proinflammatory cytokines may independently interact with IL-18. We therefore tested the ability of IL-15, a T-cell activatory cytokine that we previously detected in synovial membrane (28, 29), to synergize with IL-18. IL-15 appeared as potent as IL-12 in combining with IL-18 to promote IFN- $\gamma$  production by synovial tissues in vitro (Figure 4). Moreover, in all synovial tissues tested ( $n = 10$ ), the combination of IL-12, IL-15, and IL-18 proved optimal in inducing IFN- $\gamma$  production. The absolute levels of IFN- $\gamma$  detected ex vivo in synovial tissues, however, are usually low (30), although intracellular FACS and ELISPOT analyses indicate that a majority of synovial

T cells exhibit the potential for IFN- $\gamma$  expression (7, 8). Thus, we investigated the effect of coincident IL-10 and TGF- $\beta$  addition on IFN- $\gamma$  production in vitro. IFN- $\gamma$  levels induced by IL-18 in combination with IL-12 or IL-15 were consistently suppressed in the presence of IL-10 and TGF- $\beta$  (Figure 4;  $P = 0.002$  for SF mononuclear cells;  $P = 0.038$  for synovial membrane-derived single-cell suspensions). These data indicate that combinations of T-cell activatory cytokines, which may be expressed individually at low concentrations, can sustain synovial Th1 responses. Moreover, their functional effects are likely modified by the presence of anti-inflammatory cytokine activities.

**Enhanced synovial monokine and NO expression by IL-18.** Clinical intervention studies have clearly established the importance of TNF- $\alpha$  in RA pathogenesis (31). We therefore determined the effect of IL-18 on TNF- $\alpha$  production. IL-18 and IL-12 individually induced TNF- $\alpha$  production by both SF mononuclear cells and synovial membrane cultures (Figure 5). Combination of IL-12 with IL-18 induced synergistic enhancement of TNF- $\alpha$  production



**Figure 5**  
(a) TNF- $\alpha$  production in cultures, identical to those described in Figure 4, was determined by ELISA. Data (mean  $\pm$  SEM) are pooled from 10 individual RA patients, each cultured in triplicate. (b) Enhanced intracellular TNF- $\alpha$  expression in CD14 $^{+}$  monocytes within synovial fluid mononuclear cells measured by FACS after addition of 100 ng/mL IL-18. Data are representative of 10 similar experiments. Isotype-matched control antibody staining was less than 1%.



**Figure 6**

(a) IL-18 from synovial membrane cultures representative of 4 positive cultures; 2 were negative. (b) Upregulation of IL-18 mRNA in SFB cell lines (3rd passage,  $n = 10$  RA patients) by TNF- $\alpha$  and IL-1 $\beta$  in vitro. Immunohistological localization in SFBs using D3B6 mAb showed that IL-18 was present after (c), but not before (d), stimulation with TNF- $\alpha$  and IL-1 $\beta$ .

in both culture systems ( $P = 0.002$  for both versus medium cultures). Addition of IL-15 alone induced modest levels of TNF- $\alpha$  production, which were significantly enhanced by combination with IL-18 ( $P = 0.03$  for SF mononuclear cells;  $P = 0.013$  for synovial membrane cultures) or IL-12/IL-18 ( $P = 0.01$  and  $P = 0.002$ , respectively) (Figure 5). The presence of IL-10 and TGF- $\beta$  in combination effectively abrogated the synthesis of TNF- $\alpha$  in these cultures. To determine the primary cellular source of TNF- $\alpha$  production, we performed intracellular FACS analysis in a subset of SF cultures, which consistently revealed TNF- $\alpha$  expression in CD14 $^{+}$  macrophages, but not in CD3 $^{+}$  T lymphocytes, within 4 hours of addition of IL-18 and Brefeldin A (Figure 5c). Similar data were obtained when IL-12, IL-15, and IL-18 were added in combination (data not shown). To determine potential effects on other monokines, we investigated the ability of IL-18 to upregulate GM-CSF synthesis in synovial cultures, as GM-CSF can be independently induced by IL-18 in PBMCs (27). Significant upregulation of GM-CSF production was observed in 9 of 9 synovial membrane cultures after addition of 100 ng/mL IL-18 (medium  $270 \pm 58$  pg/mL vs. IL-18  $1,889 \pm 242$  pg/mL;  $P < 0.004$ ). No further enhancement was induced by coincident addition of either IL-12 or IL-15. These data clearly indicate that the functional potential of IL-18 in synovial membrane extends beyond Th1 regulation to include direct effects on macrophages to promote cytokine expression.

NO production is a feature of inflamed synovial membrane, where it is produced by SFBs and by macrophages (24). Because NO may regulate Th1 responses (32), we tested the ability of IL-18 to promote NO production in synovial membrane cultures. Significant induction of nitrite production was observed in 9 of 9 synovial membranes examined (medium  $1 \mu\text{M}$  vs. IL-18  $14 \pm 5.6 \mu\text{M}$ ;  $P < 0.008$ ). Maximal nitrite production observed with the cytokine cocktail, IL-18/IL-12/IL-15 ( $29 \pm 7.4 \mu\text{M}$ ), was significantly higher than that obtained with IL-18 alone ( $P = 0.03$ ).

**Proinflammatory effects of IL-18 in vivo.** Murine CIA is a useful model in which the critical role of cytokines, such as TNF- $\alpha$  and IL-1, have been characterized in vivo (11, 31). We used CIA to investigate whether IL-18 could promote articular inflammation. DBA/1 mice immunized with CII in IFA developed low incidence of mild arthritis. In contrast, mice in which recombinant murine IL-18 was coadministered during CII/IFA priming (day -1 to day 4) and challenge (day 20 to day 24) developed high incidence and severity of inflammatory arthritis ( $P < 0.01$ ; Table 2), which was comparable in severity by day 33, and in incidence by day 73, to that achieved in positive control animals that received CII in CFA. Histological examination confirmed the presence of synovial hyperplasia and inflammation and cartilage destruction (data not shown). These data clearly demonstrate that IL-18 is capable of promoting destructive inflammatory arthritis.

**Regulation of IL-18 production in synovial tissues.** IL-18 syn-



thesis has been described mainly from monocytic cells responding to bacterial products and proinflammatory cytokines. Although IL-18 mRNA was easily detected by RT-PCR, unstimulated primary synovial membrane cultures did not consistently produce IL-18 protein at levels detectable by ELISA (sensitivity, 35 pg/mL) (Figure 6a), although IL-6 was always present (data not shown). Addition of IL-1 $\beta$  and TNF- $\alpha$  induced significant IL-18 production in 4 of 6 synovial membrane cultures (Figure 6a). Because IL-18 mRNA was constitutively expressed in macrophages and in primary synovial cultures, we next sought IL-18 mRNA-negative cells of synovial origin. Histological examination had suggested that a small population of SFBs might express IL-18 *in situ*. RA SFB cultures were therefore established that did not express IL-18 mRNA, enabling us to examine directly those factors required to upregulate novel IL-18 gene expression. Addition of TNF- $\alpha$  and IL-1 $\beta$  induced IL-18 mRNA expression in 10 of 10 such SFB lines tested (Figure 6b). Induction of IL-18 protein expression was identified immunohistochemically using D3B6 (Figure 6, c and d), the specificity of which was confirmed in this culture system by effective prior neutralization with recombinant IL-18. Parallel experiments demonstrated upregulation of IL-15, but not IL-12, and mRNA and protein expression by TNF- $\alpha$  and IL-1 $\beta$  (data not shown). Together, these data suggest that monokines, themselves upregulated by IL-18, can in turn promote IL-18 gene expression and protein secretion. Moreover, under the influence of TNF- $\alpha$  and IL-1 $\beta$ , SFBs may contribute to this process, although their quantitative effect may be minor.

## Discussion

The present study set out to examine the role of IL-18 in regulating Th1 responses in RA synovial membrane. Our data suggest that IL-18 can indeed promote articular Th1 responses but may also act directly on macrophages to induce proinflammatory cytokine production. Moreover, IL-18 promoted CIA *in vivo*, suggesting that these *in vitro* observations are of pathophysiological importance.

RA is most likely a Th1-associated disease. Those T cell-derived cytokines that can be detected in synovial membrane, albeit at low levels, are of Th1 type, with relative absence of IL-4 or IL-5 (5). T-cell clones grown out of synovial tissues are similarly usually of Th1 phenotype (6). Up to 80% of synovial T cells are CCR5<sup>+</sup> (33), and when stimulated and analyzed by immunofluorescence or ELISPOT (7, 8) are found to express predominantly IFN- $\gamma$ , but not IL-4. Moreover, recent preliminary data suggest that initial peripheral blood Th1/Th2 ratios determined by intracellular FACS may predict responsiveness to disease-modifying antirheumatic drug therapy 9 months later (34). Those factors that regulate such Th1 responses, still poorly understood in RA, are therefore of considerable interest. The present report demonstrates that IL-18 can sustain Th1 cell responses in synovial membrane, through synergy with other T-cell activatory cytokines. Because variable levels of IL-12 have been detected in the RA synovium, a crucial role for IL-18 in synovitis may be to promote IL-12-dependent Th1 responses in the context of relatively low levels of IL-12 expression. Our data further suggest that IL-15 can con-

tribute to this process and may replace the requirement for IL-12, should the latter be limiting.

The paradoxical failure to detect high levels of IFN- $\gamma$  *in situ* in synovial membrane in the presence of IL-18 may reflect several factors. Anti-inflammatory cytokines, such as IL-10 and TGF- $\beta$ , are widely expressed in synovial membrane and clearly suppressed IFN- $\gamma$  synthesis *in vitro*. The duration of sustained IFN- $\gamma$  expression within a single Th1 cell after stimulation in the presence of such factors is unclear. Synovial lymphocytes, however, clearly retain their functional maturation status as exemplified by their subsequent IFN- $\gamma$  expression *ex vivo*. The inflammatory potential of IL-18 may therefore reflect a balance of pro- versus anti-inflammatory cytokines in the local milieu, in which an equilibrium can sustain Th1 phenotype without inducing persistently high levels of IFN- $\gamma$  production. An IL-18-binding protein (IL-18BP) has recently been described that is constitutively expressed in lymphoid tissues and that can regulate the contribution of IL-18 to Th1 responses *in vivo* (35). IL-18BP expression, if confirmed in synovial membrane, could further limit IFN- $\gamma$  upregulation by locally produced IL-18. Nevertheless, low numbers of IFN- $\gamma$ -expressing cells are consistently detected in RA synovium (5, 7). Our data indicate that IL-18, together with IL-12 and IL-15, can perpetuate such Th1 responses. Furthermore, IL-18R was detected on CD3<sup>+</sup> cells, likely representing a mature Th1 subset (36), and on macrophages, indicating that endogenous IL-18 expression can be biologically active. In a murine model of inflammatory arthritis, IL-18 was capable of promoting a severe, erosive inflammatory polyarthropathy. Moreover, as IL-18, but not IL-12, activates the IFN- $\gamma$  promoter directly through an AP-1 site, independent of T-cell receptor signaling (37), it is possible that IL-18, like IL-15, IL-1 $\beta$ , and IL-6, can contribute to antigen-independent T-cell activation in chronic inflammatory responses (29, 38).

Monocyte-derived cytokines occupy a central position in the pathogenesis of RA (11). Therapeutic blockade of TNF- $\alpha$  and IL-1 $\beta$ , using soluble receptors or mAb, suppresses murine CIA and RA itself (39). Clinical effects are transient, however, suggesting that critical pathways that maintain synovitis persist. Factors that upregulate TNF- $\alpha$  production include positive feedback from monokines, immune complexes, and cell contact with "cytokine-activated" T cells (38, 40). IL-18 induced high levels of TNF- $\alpha$  and GM-CSF production by synovial tissues, in synergy with IL-12

**Table 2**  
IL-18 in murine CIA

Group	Arthritic score (incidence %) <sup>a</sup>		
	Day 33	Day 53	Day 73
CFA (n = 22)	2.9 $\pm$ 0.3 (59%) <sup>b</sup>	5.1 $\pm$ 0.4 (91%) <sup>b</sup>	5.4 $\pm$ 0.4 (91%) <sup>b</sup>
CII/IFA	3.1 $\pm$ 0.7 (27%) <sup>c</sup>	5.1 $\pm$ 0.7 (65%) <sup>c</sup>	5.4 $\pm$ 0.6 (81%) <sup>b</sup>
IL-18 (n = 26)			
CII/IFA	0 $\pm$ 0 (0%)	2.3 $\pm$ 0.3 (17%)	2.2 $\pm$ 0.2 (22%)
PBS (n = 23)			

<sup>a</sup>Clinical scores (mean  $\pm$  SEM), from arthritic mice only, are combined from 2 separate experiments. Mice received CII in CFA or in IFA. CII/IFA recipients also received either IL-18 or PBS daily from day -1 to day 4 and day 20 to day 24. <sup>b</sup>P < 0.01 and <sup>c</sup>P < 0.05 for severity and incidence, respectively, compared with CII/IFA PBS control.

and IL-15. Single-cell staining revealed TNF- $\alpha$  protein in CD14<sup>+</sup> macrophages after IL-18 addition to Brefeldin A-treated synovial cells. Because no IFN- $\gamma$  secretion occurred in these cultures, a direct effect of IL-18 on TNF- $\alpha$  production by synovial macrophages is probable. IL-18 induces IL-1 $\beta$  mRNA expression directly in purified macrophages, whereas TNF- $\alpha$  production by PBMCs has been attributed to CD3/CD4<sup>+</sup> cells (27, 41). Whether this minor discrepancy is a function of the activation/maturation status of synovial versus blood macrophages requires clarification. Together these data clearly indicate that the proinflammatory activities of IL-18 in synovial membrane extend beyond Th1 cells to include macrophages.

IL-18 expression in synovial tissues in vitro was enhanced by TNF- $\alpha$  and IL-1 $\beta$ , raising the possibility of a positive feedback loop that could lead to reciprocal amplification of Th1 responses and monocyte production. Moreover, IL-18 inhibited TGF- $\beta$ -induced proliferation, induced matrix metalloproteinase and inducible NO synthase (NOS) gene expression, and enhanced glycosaminoglycan release in chondrocytes in vitro (18). IL-18 could therefore contribute to cartilage degradation, although whether synovium-derived IL-18 can contribute locally to this process remains to be determined. We have now also shown that IL-18 induced nitrite synthesis in synovial membrane cultures. Given that NO reduces IL-18 cleavage through inhibition of ICE (42), upregulation of NO release by IL-18, IL-12, or IL-15 in synovial cultures may represent an endogenous regulatory pathway for IL-18 (and IL-1 $\beta$ ) production. Compatible with this, we previously demonstrated dysregulated Th1 responses in iNOS-deficient mice (32).

IL-18 is a member of the IL-1 cytokine family that is widely expressed in RA synovium. IL-1 $\beta$  and IL-18 gene expression is differentially regulated (26). The pattern of distribution of IL-18 in synovial membrane appears distinct from that of IL-1 $\beta$ . Whereas IL-1 $\beta$  is highly expressed throughout the lining layer, interstitium, and vasculature, IL-18 is localized primarily to lymphocytic aggregates. Because ICE regulates the processing and secretion from intracellular precursors of both IL-1 $\beta$  and IL-18 (26), it seems likely that other distinct mechanisms will contribute to differential cytokine expression in discrete parts of the synovium. ICE inhibition remains an enticing therapeutic target. ICE inhibitors effectively suppress murine CIA (43). Whether such effects are associated with suppression of IL-18-dependent effects remains unclear.

A further implication of this study is that detection of a cytokine and determination of its absolute concentration in SF is unlikely to correlate directly to its relative functional importance, but should rather reflect its potential for synergy. We have identified an important role for IL-18, together with IL-15 and IL-12, in such a network within the synovial membrane. Although the mechanism of such synergy is yet to be defined, the present study provides rationale for identifying functional cytokine "cassettes" that together may be amenable to inhibition.

#### Acknowledgments

This work received financial support from the Arthritis Research Campaign, United Kingdom; The Medical Research Council; The Wellcome Trust; The Nuffield Foundation; and the MacFeat Bequest, University of

Glasgow. Clinical samples were kindly provided by J. Hunter, A. Kinninmonth, I. Stotter, R.D. Sturrock, H.A. Capell, and R. Madhok.

1. Mauri, C., Williams, R.O., Walmsley, M., and Feldmann, M. 1996. Relationship between Th1/Th2 cytokine patterns and the arthritogenic response in collagen induced arthritis. *Eur. J. Immunol.* 26:1511-1518.
2. Racke, M.K., et al. 1994. Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease. *J. Exp. Med.* 180:1961-1966.
3. Katz, J.D., Benoist, C., and Mathis, D. 1995. T helper cell subsets in insulin dependent diabetes. *Science* 268:1185-1188.
4. Mosmann, T.R., and Sad, S. 1996. The expanding universe of T cell subsets: Th1, Th2 and more. *Immunol. Today* 17:13-17.
5. Ulfgren, A.-K., Lindblad, S., Klareskog, L., Andersson, J., and Andersson, U. 1995. Detection of cytokine producing cells in the synovial membrane from patients with rheumatoid arthritis. *Ann. Rheum. Dis.* 54:654-661.
6. Miltenburg, A.M.M., van Laar, J.M., De Kuiper, R., Daha, M.R., and Breedveld, F.C. 1992. T cells cloned from human rheumatoid synovial membrane functionally represent the Th1 subset. *Scand. J. Immunol.* 35:603-610.
7. Dolhain, R.J.E.M., Heiden, A.N., Haar, N.T., Breedveld, F.C., and Miltenburg, A.M.M. 1996. Shift towards T lymphocytes with a T helper 1 cytokine secretion profile in the joints of patients with rheumatoid arthritis. *Arthritis Rheum.* 39:1961-1969.
8. Ronnelid, J., et al. 1998. Production of T cell cytokines at the single cell level in patients with inflammatory arthritides: enhanced activity in synovial fluid compared to blood. *Br. J. Rheum.* 37:7-14.
9. Gately, M.K., et al. 1998. The interleukin-12/interleukin-12 receptor system. *Ann. Rev. Immunol.* 16:495-521.
10. Morita, Y., et al. 1998. Expression of interleukin-12 in synovial tissue from patients with rheumatoid arthritis. *Arthritis Rheum.* 41:306-314.
11. Feldmann, F., Brennan, F.M., and Maini, R.N. 1996. Role of cytokines in rheumatoid arthritis. *Ann. Rev. Immunol.* 14:397-440.
12. Ushio, S., et al. 1996. Cloning of the cDNA for human IFN- $\gamma$ -inducing factor, expression in *Escherichia coli*, and studies on the biologic activities of the protein. *J. Immunol.* 156:4274-4279.
13. Gu, Y., et al. 1997. Activation of interferon-gamma inducing factor mediated by interleukin-1 $\beta$  converting enzyme. *Science* 275:206-209.
14. Okamura, H., Kashiwamura, S., Tsutsui, H., Yoshimori, T., and Nakanishi, K. 1998. Regulation of interferon- $\gamma$  production by IL-12 and IL-18. *Curr. Opin. Immunol.* 10:259-264.
15. Kohno, K., and Kurimoto, M. 1998. Interleukin 18, a cytokine which resembles IL-1 structurally and IL-12 functionally but exerts its effect independently of both. *Clin. Immunol. Immunopathol.* 86:11-15.
16. Takeda, K., et al. 1998. Defective NK cell activity and Th1 response in IL-18-deficient mice. *Immunity* 8:383-390.
17. Udagawa, N., et al. 1997. Interleukin-18 (interferon-gamma-inducing factor) is produced by osteoblasts and acts via granulocyte/macrophage colony-stimulating factor and not via interferon-gamma to inhibit osteoclast formation. *J. Exp. Med.* 185:1005-1012.
18. Olec, T., Hashimoto, S., Quach, J., and Lotz, M. 1999. IL-18 is produced by articular chondrocytes and induces proinflammatory and catabolic responses. *J. Immunol.* 162:1096-1100.
19. Rothe, H., Jenkins, N., Copeland, N., and Kolb, H. 1997. Active stage of autoimmune diabetes is associated with the expression of a novel cytokine, IGIF, which is located near Idd2. *J. Clin. Invest.* 99:469-474.
20. Kawakami, K., et al. 1997. IL-18 protects mice against pulmonary and disseminated infection with *Cryptococcus neoformans* by inducing IFN- $\gamma$  production. *J. Immunol.* 159:5528-5534.
21. Bohn, E., et al. 1998. IL-18 (IFN-gamma-inducing factor) regulates early cytokine production in, and promotes resolution of, bacterial infection in mice. *J. Immunol.* 160:299-307.
22. Chan, W.L., and Mitchison, N.A. 1982. Use of somatic cell hybrids for production of monospecific viral antibodies. *Lab. Res. Methods Biol. Med.* 15:125-141.
23. Arnett, P.C., Edworthy, S.M., and Block, D.A. 1988. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. *Arthritis Rheum.* 31:315-324.
24. McInnes, I.B., et al. 1997. Production of nitric oxide in the synovial membrane of rheumatoid and osteoarthritis patients. *J. Exp. Med.* 184:1519-1524.
25. Ruchatz, H., Leung, B.P., Wei, X.-Q., McInnes, I.B., Liew, F.Y. 1998. Soluble IL-15 receptor alpha-chain administration prevents murine collagen-induced arthritis: a role for IL-15 in development of antigen-induced immunopathology. *J. Immunol.* 160:5654-5660.
26. Puren, A.J., Fantuzzi, G., and Dinarello, C.A. 1999. Gene expression, synthesis, and secretion of interleukin 18 and interleukin 1 $\beta$  are differentially regulated in human blood mononuclear cells and mouse spleen cells. *Proc. Natl. Acad. Sci. USA* 96:2256-2261.
27. Dinarello, C.A., et al. 1998. Overview of interleukin-18: more than an interferon-gamma inducing factor. *J. Leukoc. Biol.* 63:658-664.

28. McInnes, I.B., et al. 1996. The role of interleukin-15 in T-cell migration and activation in rheumatoid arthritis. *Nat. Med.* 2:175-182.
29. McInnes, I.B., and Liew, F.Y. 1998. Interleukin 15: a proinflammatory role in rheumatoid arthritis synovitis. *Immunol. Today* 19:75-79.
30. Firestein, G.S., and Zvaifler, N.J. 1987. Peripheral blood and synovial fluid monocyte activation in inflammatory arthritis. II. Low levels of synovial fluid and synovial tissue interferon suggest that gamma-interferon is not the primary macrophage activating factor. *Arthritis Rheum.* 30:864-871.
31. Feldmann, M., Charles, P., Taylor, P., and Maini, R.N. 1998. Biological insights from clinical trials with anti-TNF therapy. *Springer Semin. Immunopathol.* 20:21-28.
32. McInnes, I.B., and Liew, F.Y. 1998. Nitric oxide and immune response. In *Nitric oxide and bone disease*. M. Hukkanen, J.M. Polak, and S.P.F. Hughes, editors. Cambridge University Press, Cambridge, United Kingdom. 8-20.
33. Loetscher, P., et al. 1998. CCR5 is characteristic of Th1 lymphocytes. *Nature* 391:344-345.
34. van der Graaff, W.L., Prins, A.P., Dijkmans, B.A., and van Lier, R.A. 1998. Prognostic value of Th1/Th2 ratio in rheumatoid arthritis. *Lancet* 351:1931.
35. Novick, D., et al. 1999. Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response. *Immunity* 10:127-136.
36. Xu, D., et al. 1998. Selective expression and functions of interleukin 18 receptor on T helper (Th) type 1 but not Th2 cells. *J. Exp. Med.* 188:1485-1492.
37. Barbulescu, K., et al. 1998. IL-12 and IL-18 differentially regulate the transcriptional activity of the human IFN-gamma promoter in primary CD4+ T lymphocytes. *J. Immunol.* 160:3642-3647.
38. McInnes, I.B., Leung, B.P., Sturrock, R.D., Field, M., and Liew, F.Y. 1997. Interleukin-15 mediates T cell-dependent regulation of tumour necrosis factor-alpha production in rheumatoid arthritis. *Nat. Med.* 3:189-195.
39. Williams, R.O., Feldmann, M., and Maini, R.N. 1994. Anti-tumour necrosis factor ameliorates joint disease in murine collagen induced arthritis. *Proc. Natl. Acad. Sci. USA* 89:9784-9788.
40. Vey, E., Zhang, J., and Day, J.-M. 1992. IFN-gamma and 1,25(OH)<sub>2</sub>D<sub>3</sub> induce on THP-1 cells distinct patterns of cell surface antigen expression, cytokine production and responsiveness to contact with activated T cells. *J. Immunol.* 149:2040-2046.
41. Puren, A.J., Fantuzzi, G., Gu, Y., Su, M.S., and Dinarello, C.A. 1998. Interleukin-18 (IFN-gamma-inducing factor) induces IL-8 and IL-1β via TNF-α production from non-CD14+ human blood mononuclear cells. *J. Clin. Invest.* 101:711-721.
42. Kim, Y.M., Talanian, R.V., Li, J., and Billiar, T.R. 1998. Nitric oxide prevents IL-1β and IFN-γ-inducing factor (IL-18) release from macrophages by inhibiting caspase-1 (IL-1β-converting enzyme). *J. Immunol.* 161:122-128.
43. Ku, G., Faust, T., Lauffer, L.L., Livingston, D.J., and Harding, M.W. 1996. Interleukin-1β converting enzyme inhibition blocks progression of type II collagen-induced arthritis in mice. *Cytokine* 8:377-386.



**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☒ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**